Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery. — CFSMEATLAS
Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery.
Gómez-Mora, Elisabet, Carrillo, Jorge, Urrea, Víctor et al. · Frontiers in immunology · 2020 · DOI
Quick Summary
This study looked at how freezing blood samples affects the ability to detect immune cell changes in ME/CFS patients. Researchers compared fresh blood samples with frozen ones from ME/CFS patients and healthy people, testing various immune markers. They found that some immune markers stay reliable after freezing, but others—particularly certain natural killer cell markers—change significantly, which could make them unreliable for future research.
Why It Matters
This research addresses a critical technical challenge in ME/CFS biomarker discovery: the reliability of frozen blood samples used in research biobanks. By identifying which immune markers are distorted by freezing, this work helps researchers design better studies and interpret past findings more accurately. This is essential for developing trustworthy biological tests that could eventually aid diagnosis and understanding of ME/CFS.
Observed Findings
NK cell markers CD25 and CD69 were significantly elevated after cryopreservation and thawing
NK cell marker NKp46 expression was markedly reduced in frozen samples compared to fresh
T cell markers (Treg subsets, CD56, CD57, effector CD8) remained stable after biobanking
No significant differences in Treg or NK cell subsets were detected between ME/CFS patients and controls in cryopreserved samples
Cytokine production functionality was retained in frozen PBMC samples
Inferred Conclusions
Long-term cryopreservation introduces artifactual changes in certain NK cell markers that may confound biomarker discovery research in ME/CFS
Previously reported immune abnormalities in ME/CFS may have been affected by biobanking procedures, requiring revalidation with fresh samples or improved preservation methods
Standardized protocols for biomarker assessment must account for marker-specific cryostability to ensure reliable multisite ME/CFS studies
Future biomarker research requires novel assessment tools designed specifically for cryopreserved immune cells in ME/CFS
Remaining Questions
Which specific cryopreservation or thawing protocols could minimize artifact in unstable markers like NKp46?
What This Study Does Not Prove
This study does not prove whether specific immune abnormalities actually exist in ME/CFS, since the biobanking process itself may have obscured or created apparent differences. It also does not establish which immune markers would be stable in other tissue types or different preservation methods. The small sample size (18 per group) limits generalizability to broader ME/CFS populations.
Would different tissue types or sample collection methods yield more stable immune markers for ME/CFS research?
What are the mechanisms causing NK cell activation markers to increase during freezing and thawing?
Can fresh blood sampling protocols be standardized across multiple research sites to enable reliable immune marker comparison in ME/CFS without biobanking confounds?